Literature DB >> 27519954

Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.

Qing Ye1, Fang-Qi Gong2, Shi-Qiang Shang3, Jian Hu4.   

Abstract

Kawasaki disease (KD) has become the most common cause of acquired heart disease in children and is also a risk factor for ischemic heart disease in adults. However, Kawasaki disease lacks specific laboratory diagnostic indices. Thus, this study analyzed the T cell activation profiles of Kawasaki disease and assessed their value in the diagnosis of Kawasaki disease and the prediction of intravenous immunoglobulin (IVIG) sensitivity. We analyzed human leukocyte antigen-DR (HLA-DR), CD69 and CD25 expression on peripheral blood CD4+ and CD8+ T cells during the acute phase of KD. We compared the percentages of HLA-DR+/CD69+/CD25+ T cells in the CD4+ and CD8+ T cell populations of IVIG-effective and IVIG-resistant groups. Receiver operating characteristic curves were used to assess the diagnostic value of the above parameters. The median percentage of CD8+HLA-DR+ T cells and the median ratio of CD8+HLA-DR+ T cells/CD8+CD25+ T cells were significantly elevated in the patient group compared with those in the control group during the acute phase of KD. Regarding the diagnosis of Kawasaki disease, the area under the ROC curve was 0.939 for the percentage of CD8+HLA-DR+ T cells. There was a significant difference in the ratio of CD8+HLA-DR+ T cells/CD8+CD69+ T cells between IVIG-resistant patients and IVIG-sensitive patients. Regarding IVIG sensitivity, the area under the ROC curve was 0.795 for it. Excessive CD8+ T cell activation, as well as an imbalance between CD8+ T cell activation and inhibition, underlies the pathogenesis of Kawasaki disease. The percentage of CD8+ HLA-DR+ T cells may be used as an index to diagnose Kawasaki disease. IVIG inhibits CD8+ T cell activation, but excessive CD8+ T cell activation may cause IVIG resistance. The ratio of CD8+HLA-DR+ T cells/CD8+CD69+ T cells may be used as a predictor of IVIG sensitivity.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  CD8+HLA-DR+ T cells; Flow cytometry; Immune activation; Kawasaki disease; ROC curve

Mesh:

Substances:

Year:  2016        PMID: 27519954     DOI: 10.1016/j.clim.2016.08.012

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  12 in total

1.  Vasculitis syndromes: Diagnostic and prognostic roles for T-cell markers in Kawasaki disease.

Authors:  Caroline Barranco
Journal:  Nat Rev Rheumatol       Date:  2016-08-25       Impact factor: 20.543

2.  The risk of hospitalization for respiratory tract infection (RTI) in children who are treated with high-dose IVIG in Kawasaki Disease: a nationwide population-based matched cohort study.

Authors:  Wei-Te Lei; Chien-Yu Lin; Yu-Hsuan Kao; Cheng-Hung Lee; Chao-Hsu Lin; Shyh-Dar Shyur; Kuender-Der Yang; Jian-Han Chen
Journal:  PeerJ       Date:  2018-03-22       Impact factor: 2.984

Review 3.  Vasculitis Pathogenesis: Can We Talk About Precision Medicine?

Authors:  Seza Ozen; Ezgi Deniz Batu
Journal:  Front Immunol       Date:  2018-08-14       Impact factor: 7.561

4.  Variation in IL-21-secreting circulating follicular helper T cells in Kawasaki disease.

Authors:  Meng Xu; Yanfang Jiang; Jian Zhang; Yan Zheng; Deying Liu; Lishuang Guo; Sirui Yang
Journal:  BMC Immunol       Date:  2018-12-27       Impact factor: 3.615

Review 5.  Kawasaki Disease: The Role of Immune Complexes Revisited.

Authors:  Stephanie Menikou; Paul R Langford; Michael Levin
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

Review 6.  Convalescent plasma in Covid-19: Possible mechanisms of action.

Authors:  Manuel Rojas; Yhojan Rodríguez; Diana M Monsalve; Yeny Acosta-Ampudia; Bernardo Camacho; Juan Esteban Gallo; Adriana Rojas-Villarraga; Carolina Ramírez-Santana; Juan C Díaz-Coronado; Rubén Manrique; Ruben D Mantilla; Yehuda Shoenfeld; Juan-Manuel Anaya
Journal:  Autoimmun Rev       Date:  2020-05-05       Impact factor: 9.754

7.  Utility of Soluble CD163 in the Clinical Management of Patients With Kawasaki Disease.

Authors:  Yoshihiro Azuma; Yasuo Suzuki; Seigo Okada; Chie Matsuguma; Hiroyuki Wakiguchi; Yuji Ohnishi; Takashi Furuta; Akiko Miyake; Hiroki Yasudo; Kiyoshi Ichihara; Shouichi Ohga; Shunji Hasegawa
Journal:  Front Pediatr       Date:  2020-04-07       Impact factor: 3.418

8.  Activin a suppresses peripheral CD8+ T lymphocyte activity in acute-phase Kawasaki disease.

Authors:  Qian Wu; Ruohang Weng; Yongbin Xu; Linlin Wang; Yanyan Huang; Jun Yang
Journal:  BMC Immunol       Date:  2021-02-23       Impact factor: 3.615

Review 9.  High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.

Authors:  Xiaosheng Liu; Wei Cao; Taisheng Li
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

10.  The elevated serum levels of calcineurin and nuclear factor of activated T-cells 1 in children with Kawasaki disease.

Authors:  Yameng Sun; Jingjing Liu; Zhimin Geng; Yijing Tao; Fenglei Zheng; Ying Wang; Songling Fu; Wei Wang; Chunhong Xie; Yiying Zhang; Fangqi Gong
Journal:  Pediatr Rheumatol Online J       Date:  2020-03-17       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.